At the Asembia Specialty Pharmacy Summit 2017, Precision for Value’s Jorge Font spoke about his presentation with Marie Rosenthal from Specialty Pharmacy Continuum on the significant impact big employers are having in revising the approaches to specialty pharmacy benefit administration and pricing. Font shared his perspective that the real payers are, in fact, employers.
Precision for Value’s Jeremy Schafer talks with Managed Healthcare Executive about a recent Precision HCV survey, highlighting unmet needs cited by payers, and what can be done to encourage payers to ease coverage policies for the next wave of HCV drugs.
Congratulations to Precision Health Economics, and in particular the Evidence Strategy, Generation, and Communication (ESGC) practice group, for their outstanding efforts in support of the development of new legislation and FDA guidelines allowing biopharmaceutical manufacturers to more proactively share clinical and economic information with population health decision-makers on emerging therapies.
Precision for Value’s Larry Blandford offers a new commentary in STAT First Opinion, insisting that payers and the pharmaceutical industry come together to develop a value-based drug reimbursement system. He suggests taking a page from the playbook developed for electronic prescribing as the key to moving forward.
Congratulations to the clinical trial and regulatory teams at Precision for Medicine: The FDA has just announced that the Philips PIPS (Philips IntelliSite Pathology Solution) has been approved through the de novo premarket review pathway as the first digital pathology solution for primary diagnostic use in the US.
This regulatory clearance signals a significant leap forward for the pathology services industry, and is expected to greatly boost adoption of digital pathology and collaboration.
Precision provided instrumental support to Philips in achieving this approval, monitoring the pivotal trial and working directly on the FDA strategy, including the successful effort to down-classify the system from a PMA Class III device to a Class II device (representing devices of a new type with low-to-moderate risk). This down-classification not only shortened the review time, but also reduces the regulatory burden going forward and streamlines the process for bringing incremental innovations to the US market.
For more information, click the link below to view the FDA press release.
Precision’s David Parker, PhD, senior vice president, diagnostics solutions, recently spoke with Clinical OMICs Editor-in-Chief Chris Anderson about some of the issues inherent in CDx development relationships.
FiercePharma interviews precisioneffect’s Carolyn Morgan and Deborah Lotterman, showcasing the creative concepts behind Precision’s buzz-worthy Boston subway takeover ad campaign.
Congratulations to our CDM and EDC teams from Precision Oncology and Precision for Medicine for being recognized by Oracle with the Excellence in Industry Service–Americas Award for 2017! Oracle was pleased to recognize Precision as an industry-leading, niche CRO dedicated to oncology studies and precision medicine initiatives. Another great example of the integration synergy generated on an ongoing basis—with Precision Oncology providing Oracle with clinical data management and Precision for Medicine providing electronic data capture builds.
Jeremy Schafer and Maureen Hennessey promote antimicrobial stewardship in a new commentary for Managed Healthcare Executive, offering 4 specific steps: rewarding antimicrobial stewardship, leveraging quality scores, implementing appropriate controls, and the establishment of patient education campaigns.
In the latest edition of Life Science Leader, Precision Oncology president Pat Devitt Risse contributes a new guest column: “Bet On Biomarkers for Better Outcomes.” In the article, Pat advocates for greater use of biomarkers used to accurately pinpoint the patient population that will benefit from a drug during clinical trials.